B7461001 - PF-06463922 in Small Cell Lung Cancer

• Research type

  Research Study

• Full title

  Phase 1/2 Study of PF 06463922 (an ALK/ROS1 Tyrosine Kinase Inhibitor) in Patients with Advanced Non-Small Cell Lung Cancer Harboring Specific Molecular Alterations

• IRAS ID

  157592

• Contact name

  Gemma Sheppard

• Contact email

  gemma.sheppard@inventivhealth.com

• Sponsor organisation

  Pfizer Inc,

• Eudract number

  2013-002620-17

• Clinicaltrials.gov Identifier

  NCT01970865

• Duration of Study in the UK

  3 years, 3 months, 1 days

• Research summary

  Research Summary & Summary of Results:

  https://www.pfizer.com/science/clinical-trials/plain-language-study-results-summaries/study-pf-06463922-alkros1-inhibitor
  

• REC name

  North West - Liverpool Central Research Ethics Committee

• REC reference

  14/NW/1202

• Date of REC Opinion

  11 Nov 2014

• REC opinion

  Further Information Favourable Opinion